Aptinyx
Evanston
Illinois
United States
114 articles with Aptinyx
-
Aptinyx to Participate in H.C. Wainwright Global Investment Conference
5/18/2022
Aptinyx Inc. announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022.
-
Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting
5/17/2022
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be presented in a poster at the American Psychiatric Association Annual Meeting being held May 21 – 25, 2022 in New Orleans, LA.
-
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
5/12/2022
Aptinyx Inc. reported financial results for the first quarter of 2022 and highlighted recent progress across the company’s pipeline of novel, clinical-stage, NMDA receptor modulators.
-
Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting
4/29/2022
Aptinyx Inc. today presented data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) at the Society of Biological Psychiatry (SOBP) Annual Meeting, being held April 28 – April 30, 2022 in New Orleans, Louisiana.
-
Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
4/27/2022
Aptinyx Inc. today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022 at 5:00 p.m. ET to report first quarter 2022 financial results and discuss recent business highlights.
-
Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783
4/20/2022
Aptinyx Inc. announced that data from preclinical studies evaluating NYX-783, a novel NMDA receptor positive allosteric modulator, in models of post-traumatic stress disorder were published in the journal, Molecular Psychiatry.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
4/7/2022
Aptinyx Inc. today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN).
-
Aptinyx therapeutic NYX-2925, intended to treat painful diabetic peripheral neuropathy failed to produce significant results. Here is why it happened.
-
Aptinyx Reports Fourth Quarter and Full Year 2021 Results and Highlights
3/23/2022
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2021 and provided updates across the company’s pipeline of novel NMDA receptor modulators.
-
Aptinyx to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, March 23, 2022
3/9/2022
Aptinyx Inc. today announced that the company will host a conference call and live webcast on Wednesday, March 23, 2022 at 5:00 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights.
-
Aptinyx to Participate in the 42nd Annual Cowen Health Care Conference
3/1/2022
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in the Neuropsychiatry Panel discussion at the 42nd Annual Cowen Health Care Conference.
-
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia
2/28/2022
Aptinyx Inc. today announced the completion of enrollment of 305 patients in the company’s ongoing Phase 2b study of NYX-2925 in fibromyalgia.
-
Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development Programs
2/9/2022
Aptinyx Inc. will host a virtual portfolio review event today beginning at 10:00 a.m. ET. Presented in a live webcast format, the company will discuss its approach to the development of novel NMDA receptor modulators.
-
Aptinyx to Present at the SVB Leerink 11th Annual Global Healthcare Conference
2/8/2022
Aptinyx Inc. today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET.
-
BioSpace Movers & Shakers, Feb. 4
2/4/2022
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers. -
Aptinyx Announces Formation of Scientific Advisory Board
2/3/2022
Aptinyx Inc. today announced the formation of its Scientific Advisory Board.
-
Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022
1/6/2022
Aptinyx Inc. today provided a corporate update and highlighted development milestones anticipated in 2022.
-
Right now, Kidd’s focus is on ensuring the company is ready for late-stage development and commercialization activities.
-
Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022
12/20/2021
Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022.